Search Results 41-50 of 11389 for MOTS-c Analogue

  1. Study Of INCB053914 In Subjects With Advanced Malignancies - Mayo Clinic

    About this study. This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor ...

  2. A Study To Evaluate ASP0367 In Participants With Primary Mitochondrial Myopathy (MOUNTAINSIDE) - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness, safety and tolerability of ASP0367 in participants with Primary Mitochondrial Myopathy (PMM).

  3. ... MOT/DIFF,271 300000020,HC APOB APOLIPOPROTEIN E ... C CONFIRM TYPING LR,347 300000206,HC IGH GENE ... ANALOGS 5>,274 301000468,HC ORGANIC ACID 1 ...

  4. Center for Cell Signaling in Gastroenterology (C-SiG)

    The Center for Cell Signaling in Gastroenterology (C-SiG) at Mayo Clinic studies the signaling pathways in gastrointestinal cells to treat GI diseases.

  5. Rem-422, An MYB MRNA Degrader, In Patients With Relapsed/Refractory AML Or Higher-Risk MDS - Mayo Clinic

    Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Primary immunodeficiency. Current or expected need for daily systemic ...

  6. A Study to Assess AC220 Given in Combination with Induction and Consolidation Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) - Mayo Clinic

    A known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen. Had major surgery within 4 weeks prior to the start of ...

  7. Clinical trials - Oncology (Medical)

    All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 ... Go to page 99 · Go to page 1010 · Go to page ...

  8. Publications - Thomas V. Colby, M.D. - Mayo Clinic

    Rossi G, Cavazza A, Colby TV. Pathology of sarcoidosis. Clin Rev Allergy Immunol. 2015 Aug; 49(1):36-44. View PubMed; Kim SY, Diggans J, ...

  9. Radiation Therapy Clinical Trials

    ... 9 weeks) with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of the treatments are similar or better. Genomic ...

  10. Phase I/II Trial To Investigate BI 836858 In Myelodysplastic Syndromes - Mayo Clinic

    Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in ...